Company news
MediciNova, Inc. news in 2025
MediciNova, Inc.'s news releases, calls and decks from 2025, newest first.
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
December 18, 2025
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
December 8, 2025
Message from the CEO to MediciNova Shareholders
December 1, 2025
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
November 18, 2025
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
November 6, 2025
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
November 4, 2025
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
October 30, 2025
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
October 6, 2025
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
September 22, 2025
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
September 16, 2025
MediciNova Provides Shareholder Update on Key Developments
September 8, 2025
MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
August 26, 2025
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
July 31, 2025
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
July 24, 2025
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
April 14, 2025
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
April 8, 2025
Decks in 2025
- Investor Presentation (March 2025)
Investor deck · 17 slides · March 2025